Although prioritized through computational rationale (Figure 5, A–E), we selected GIV (Figure 5B) because of 3 key reasons: First, as a large multi-modular protein that integrates signals from diverse classes of receptors and signaling pathways, GIV drives tumor cell aggressiveness — stemness (43), survival after DNA damage (44), invasiveness (44), chemoresistance (45), and acquisition of metastatic potential (46) — in multiple cancers, including breast (47), and is considered to be a metastasis-related protein (48) (Figure 6A). Here, CCDC88A is linked to neoplasm.